Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Operating Leases (2021 - 2025)

Krystal Biotech's Operating Leases history spans 5 years, with the latest figure at $9.3 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 54.52% year-over-year to $9.3 million; the TTM value through Dec 2025 reached $9.3 million, up 54.52%, while the annual FY2025 figure was $9.3 million, 54.52% up from the prior year.
  • Operating Leases for Q4 2025 was $9.3 million at Krystal Biotech, up from $7.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $9.7 million in Q2 2025 and bottomed at $6.0 million in Q4 2024.
  • The 5-year median for Operating Leases is $7.4 million (2022), against an average of $7.5 million.
  • The largest annual shift saw Operating Leases fell 10.2% in 2023 before it surged 54.52% in 2025.
  • A 5-year view of Operating Leases shows it stood at $7.0 million in 2021, then rose by 5.57% to $7.4 million in 2022, then decreased by 10.2% to $6.6 million in 2023, then dropped by 8.7% to $6.0 million in 2024, then soared by 54.52% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Operating Leases are $9.3 million (Q4 2025), $7.8 million (Q3 2025), and $9.7 million (Q2 2025).